Volume 6.40 | Oct 23

Prostate Cell News 6.40 October 23, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
Study Shows Deadly Prostate Cancer Cells Have Stem Cell Qualities
Scientists showed that the cells responsible for generating deadly prostate cancer share some genetic qualities with the tissue-specific stem cells that naturally reside in the healthy prostate. [Press release from University of California, Los Angeles discussing online prepublication in Proceedings of the National Academy of Sciences] Press Release | Abstract | Full Article
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

Targeting Cancer Stem Cell in Castration Resistant Prostate Cancer
The authors demonstrated that immortalized normal human prostate epithelial cells, which appeared non-tumorigenic in vivo, become tumorigenic and acquire stem cell phenotype after knocking down a tumor suppressor gene. [Clin Cancer Res] Abstract

NFATc1 Promotes Prostate Tumorigenesis and Overcomes PTEN Loss-Induced Senescence
Researchers found the upregulation of nuclear factor of activated T cells c1 (NFATc1) in human prostate cancer (PCa) and cultured PCa cells, but not in normal prostates and non-tumorigenic prostate cells. [Oncogene] Abstract

Glucocorticoid Receptor Antagonism Reverts Docetaxel-Resistance in Human Prostate Cancer
The authors studied the role of the glucocorticoid receptor (GR) in docetaxel-resistant prostate cancer in order to improve current prostate cancer therapies. GR expression was analyzed in a tissue microarray of primary prostate cancer specimens from chemo-naïve and docetaxel-treated patients, and in cultured prostate cancer cell lines with acquired docetaxel-resistance. [Endocr Relat Cancer] Abstract

Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the ERβ-KLF5 Pathway
Scientists demonstrated that estrogen (E2) has biphasic effects on prostate tumor growth. A lower dose of E2 increased tumor growth in mouse xenograft models using DU145 and PC-3 human prostate cancer cells, whereas a higher dose significantly decreased tumor growth. [Mol Cell Biol] Abstract

Enhanced G2/M Arrest, Caspase Related Apoptosis and Reduced E-Cadherin Dependent Intercellular Adhesion by Trabectedin in Prostate Cancer Stem Cells
Investigators studied the effect of trabectedin in cell proliferation, cell cycle progression, apoptosis and spheroid formation in prostate cancer stem cells. [PLoS One] Full Article

Celastrol Induces Autophagy by Targeting AR/miR-101 in Prostate Cancer Cells
The authors found that androgen receptor (AR) played a negative role in AR degrader celastrol-induced autophagy. Knockdown of AR in AR-positive prostate cancer cells resulted in enhanced autophagy. [PLoS One] Full Article

Inhibition of Fatty Acid Synthase Sensitizes Prostate Cancer Cells to Radiotherapy
Researchers examined the potential of fatty acid synthase inhibition to sensitize prostate cancer cells to radiotherapy. The efficacy of C75 alone or in combination with X irradiation was examined in monolayers and in multicellular tumor spheroids. [Radiat Res] Abstract

Krüppel-Like Factor 5 Promotes Apoptosis Triggered by Tumor Necrosis Factor α in LNCaP Prostate Cancer Cells via Up-Regulation of Mitogen-Activated Protein Kinase Kinase 7
Scientists identified how Krüppel-like factor 5 and tumor necrosis factor α pathway, which can induce apoptosis in cancer, regulate each other in LNCaP prostate cancer cells. [Urol Oncol] Abstract


Pharmacokinetics, Antitumor Activity, and Safety of ODM-201 in Patients with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: An Open-Label Phase I Study
Researchers evaluated the pharmacokinetics of ODM-201 tablet products and preliminary long-term safety, tolerability, and antitumor activity of ODM-201 in chemotherapy-naive men with metastatic castration-resistant prostate cancer. [Eur Urol] Abstract

Efficacy and Safety of Leuprorelin Acetate 6-Month Depot in Prostate Cancer Patients: A Phase III, Randomized, Open-Label, Parallel-Group, Comparative Study in Japan
Investigators assess the non-inferiority of a six-month depot formulation of TAP-144-SR 22.5 mg to a three-month depot formulation of TAP-144-SR 11.25 mg in prostate cancer patients in Japan. [Jpn J Clin Oncol] Abstract

Learn More: Standardized Tools for Cancer Research
The Biology and Clinical Implications of Prostate Cancer Dormancy and Metastasis
The authors explore novel ideas on the detection, heterogeneous transcriptomic profiles, molecular and cellular mechanisms of dormancy, and potential mechanisms underlying dormancy escape by disseminated tumor cells. [J Mol Med] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
Prostate Cancer Foundation Awards Over $3.8 Million to Early Career Scientists
The Prostate Cancer Foundation announced 19 new Young Investigator Awards at the 22nd Annual Scientific Retreat in Washington, DC. Awardees were selected from a pool of 107 applicants from 65 institutions in 9 countries. [The Prostate Cancer Foundation] Press Release

Minomic: Agreement to Begin First-In-Human Trial of Novel Prostate Cancer Imaging Agent
Minomic International Ltd has struck an important agreement to launch the first human study of its novel monoclonal antibody technology as an imaging agent to detect prostate, pancreatic and bladder cancers. [Minomic International Ltd (Business Wire)] Press Release

From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Keystone Symposium – Molecular and Cellular Basis of Growth and Regeneration
January 10-14, 2016
Breckenridge, United States

Visit our events page to see a complete list of events in the prostate cell community.
NEW Group Leader Position – Cancer Research (Oslo University Hospital)

Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Clinical Research Fellow – Prostate Cancer Biology (Cancer Research UK Manchester Institute)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us